Literature DB >> 22298976

Etanercept treatment to enable successful hepatitis C virus clearance in a patient with rheumatoid arthritis.

Alison B Jazwinski1, Janet Jezsik, Stacy P Ardoin, Rex M McCallum, Hans L Tillmann.   

Abstract

Entities:  

Year:  2011        PMID： 22298976      PMCID： PMC3264933     

Source DB:  PubMed          Journal:  Gastroenterol Hepatol (N Y)        ISSN： 1554-7914


× No keyword cloud information.
  14 in total

1.  Increased peripheral T cell reactivity to microbial antigens and collagen type II in rheumatoid arthritis after treatment with soluble TNFalpha receptors.

Authors:  L Berg; J Lampa; S Rogberg; R van Vollenhoven ; L Klareskog
Journal:  Ann Rheum Dis       Date:  2001-02       Impact factor: 19.103

2.  Induction of tumour necrosis factor (TNF) receptor type p55 and p75 in patients with chronic hepatitis C virus (HCV) infection.

Authors:  B Kallinowski; K Haseroth; G Marinos; C Hanck; W Stremmel; L Theilmann; M V Singer; S Rossol
Journal:  Clin Exp Immunol       Date:  1998-02       Impact factor: 4.330

3.  Etanercept as an adjuvant to interferon and ribavirin in treatment-naive patients with chronic hepatitis C virus infection: a phase 2 randomized, double-blind, placebo-controlled study.

Authors:  Nizar N Zein
Journal:  J Hepatol       Date:  2005-03       Impact factor: 25.083

4.  Interferon (IFN)-gamma-inducible protein-10: association with histological results, viral kinetics, and outcome during treatment with pegylated IFN-alpha 2a and ribavirin for chronic hepatitis C virus infection.

Authors:  Ana I Romero; Martin Lagging; Johan Westin; Amar P Dhillon; Lynn B Dustin; Jean-Michel Pawlotsky; Avidan U Neumann; Carlo Ferrari; Gabriele Missale; Bart L Haagmans; Solko W Schalm; Stefan Zeuzem; Francesco Negro; Elke Verheij-Hart; Kristoffer Hellstrand
Journal:  J Infect Dis       Date:  2006-08-29       Impact factor: 5.226

5.  Activation of tumor necrosis factor-alpha system in chronic hepatitis C virus infection.

Authors:  D R Nelson; H L Lim; C G Marousis; J W Fang; G L Davis; L Shen; M S Urdea; J A Kolberg; J Y Lau
Journal:  Dig Dis Sci       Date:  1997-12       Impact factor: 3.199

6.  Treatment with monoclonal anti-tumor necrosis factor alpha antibody results in an accumulation of Th1 CD4+ T cells in the peripheral blood of patients with rheumatoid arthritis.

Authors:  M M Maurice; W L van der Graaff; A Leow; F C Breedveld; R A van Lier; C L Verweij
Journal:  Arthritis Rheum       Date:  1999-10

7.  Exacerbation of symptoms of autoimmune disease in patients receiving alpha-interferon therapy.

Authors:  K C Conlon; W J Urba; J W Smith; R G Steis; D L Longo; J W Clark
Journal:  Cancer       Date:  1990-05-15       Impact factor: 6.860

8.  Safety of anti-tumor necrosis factor-alpha therapy in patients with rheumatoid arthritis and chronic hepatitis C virus infection.

Authors:  Clodoveo Ferri; Gianfranco Ferraccioli; Daniela Ferrari; Mauro Galeazzi; Giovanni Lapadula; Carlomaurizio Montecucco; Giovanni Triolo; Gabriele Valentini; Guido Valesini
Journal:  J Rheumatol       Date:  2008-08-01       Impact factor: 4.666

9.  Chronic exposure to tumor necrosis factor (TNF) in vitro impairs the activation of T cells through the T cell receptor/CD3 complex; reversal in vivo by anti-TNF antibodies in patients with rheumatoid arthritis.

Authors:  A P Cope; M Londei; N R Chu; S B Cohen; M J Elliott; F M Brennan; R N Maini; M Feldmann
Journal:  J Clin Invest       Date:  1994-08       Impact factor: 14.808

10.  IL-1 beta and TNF-alpha produced by peripheral blood mononuclear cells before and during interferon therapy in patients with chronic hepatitis C.

Authors:  Y Kishihara; J Hayashi; E Yoshimura; K Yamaji; K Nakashima; S Kashiwagi
Journal:  Dig Dis Sci       Date:  1996-02       Impact factor: 3.199
View more
  4 in total

1.  Hepatitis C virus treatment complicated by rheumatoid arthritis.

Authors:  Meredith Borman; Mark G Swain
Journal:  Gastroenterol Hepatol (N Y)       Date:  2011-11

2.  Etanercept attenuates myocardial ischemia/reperfusion injury by decreasing inflammation and oxidative stress.

Authors:  Mei Yang; Jianchang Chen; Jing Zhao; Mei Meng
Journal:  PLoS One       Date:  2014-09-26       Impact factor: 3.240

Review 3.  Treatment of Hepatitis C in Patients Undergoing Immunosuppressive Drug Therapy.

Authors:  Kohtaro Ooka; Joseph K Lim
Journal:  J Clin Transl Hepatol       Date:  2016-08-10

4.  Chikungunya virus time course infection of human macrophages reveals intracellular signaling pathways relevant to repurposed therapeutics.

Authors:  Madison Gray; Israel Guerrero-Arguero; Antonio Solis-Leal; Richard A Robison; Bradford K Berges; Brett E Pickett
Journal:  PeerJ       Date:  2022-03-21       Impact factor: 2.984
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.